USANA Health Sciences (NYSE:USNA) Posts Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Key Points

• Q1 beat: USANA reported EPS of $0.61, topping the $0.44 consensus by $0.17 and revenue of $250.22M vs. $240.99M, and updated FY2026 guidance to 1.950–2.290 EPS.
• Shares traded up to $19.19 after the release, but the stock (market cap $354.13M, P/E 34.89) faces downward pressure from recent analyst downgrades, giving an average rating of "Reduce".

USANA Health Sciences (NYSE:USNA - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.17, FiscalAI reports. The company had revenue of $250.22 million during the quarter, compared to the consensus estimate of $240.99 million. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%. USANA Health Sciences updated its FY 2026 guidance to 1.950-2.290 EPS.

USANA Health Sciences Stock Performance

NYSE USNA traded up $0.63 during trading hours on Tuesday, hitting $19.19. The company had a trading volume of 97,344 shares, compared to its average volume of 124,924. The firm has a 50 day simple moving average of $18.58 and a 200 day simple moving average of $19.73. USANA Health Sciences has a 52 week low of $16.60 and a 52 week high of $38.32. The firm has a market capitalization of $354.13 million, a price-to-earnings ratio of 34.89, a PEG ratio of 0.83 and a beta of 0.77.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on USNA. Wall Street Zen downgraded USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday. Zacks Research downgraded USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of USANA Health Sciences in a research note on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Reduce".

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, insider Joshua Foukas sold 4,461 shares of the firm's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $21.34, for a total value of $95,197.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.82% of the stock is currently owned by insiders.

Institutional Trading of USANA Health Sciences

Several institutional investors and hedge funds have recently modified their holdings of USNA. AQR Capital Management LLC raised its holdings in shares of USANA Health Sciences by 82.8% in the 1st quarter. AQR Capital Management LLC now owns 21,845 shares of the company's stock valued at $589,000 after acquiring an additional 9,894 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of USANA Health Sciences in the 1st quarter valued at about $687,000. Russell Investments Group Ltd. raised its holdings in shares of USANA Health Sciences by 31.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 13,377 shares of the company's stock valued at $408,000 after acquiring an additional 3,198 shares in the last quarter. Quantbot Technologies LP raised its holdings in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock valued at $121,000 after acquiring an additional 646 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of USANA Health Sciences in the 2nd quarter valued at about $422,000. Hedge funds and other institutional investors own 54.25% of the company's stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.